• Link to X
  • Hi,
  • Member Dashboard
  • Log Out
  • Contact
Grasp Cancer
  • About
    • What We Do
    • For Researchers
    • For Advocates
    • Our Team
    • Board of Advisors
    • Careers
  • Join Us
  • Events
  • News
  • Login
  • Donate
  • Menu Menu
  • About
    • What We Do
    • For Advocates
    • For Researchers
    • Our Team
    • Board of Advisors
    • Careers
  • Events
  • Join Us
  • News
  • Contact
  • Member Dashboard
  • Log In
  • Log Out
  • Donate

SABCS25 – Group 3E: Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance

SABCS25 – Group 3D: HR+ Locally Advanced and Metastatic Breast Cancer; PIK3CA Mutations; Treatment Resistance

SABCS25 – Group 3C: HER2+ and HER2-low Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance

SABCS25 – Group 3B: Early Stage Breast Cancer; Liquid Biopsy

SABCS25 – Group 3A: BEGINNER TRACK: Metastatic Breast Cancer; Side Effects; Symptom Management

SABCS25 – Group 2E: Metastatic Breast Cancer; Brain Metastasis Risk Prediction

SABCS25 – Group 2D: HR+ Metastatic Breast Cancer; ESR1 Mutations; Targeted Therapies; Treatment Resistance

SABCS25 – Group 2C: HER2-negative Metastatic Breast Cancer; Tumor Immune Microenvironment

SABCS25 – Group 2B: Lobular Breast Cancer; Disease Monitoring; Liquid Biopsy

SABCS25 – Group 2A: BEGINNER TRACK: Racial and Health Disparities; Side Effects; Symptom Management

Page 2 of 3123

GUIDING RESEARCHERS & ADVOCATES TO SCIENTIFIC PARTNERSHIPS

  • What We Do
  • For Researchers
  • For Advocates
  • Our Team
  • Board of Advisors
  • Careers
  • Donate
@2026 Grasp Cancer | All rights reserved. | Site by Dot Think
  • Link to X
Scroll to top Scroll to top Scroll to top